Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
FELIQS logo — An early clinical-stage biotech focusing on ophthalmology. P...

FELIQS

An early clinical-stage biotech focusing on ophthalmology. Preparing to initiate phase 1b/2 study for ROP in 2025.

Founded 2019 Japan Japan 2 employees Biotechnology, Health Care +2

General Information

Company Name FELIQS
Founded Year 2019
Location Japan Japan
Employees 2
Industries Biotechnology, Health Care, Life Sciences +1
Social

BounceWatch is an independent company data service, not affiliated with FELIQS. To contact FELIQS, visit feliqs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does FELIQS compare?

A PDF of FELIQS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting FELIQS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About FELIQS

FELIQS is a preclinical-stage biotech startup based in Japan, focusing on ophthalmology and ferroptosis. The company has secured a seed round of $2.5 million to develop a portfolio of two patent-protected drug product candidates targeting Retinopathy of Prematurity (ROP) and Age-related Macular Degeneration (AMD) - two lucrative multi-billion-dollar markets in ophthalmology and neonatology. The first candidate, FLQ-101, is a lipid peroxidation inhibitor intended to prevent ROP and is scheduled for Phase I/II dosing in the US in 2024. The second candidate, FLQ-104, is a proprietary lipid peroxidation and ferroptosis inhibitor for earlier AMD intervention and is currently in the discovery stage in the US. FELIQS utilizes a proprietary screening platform targeting lipid peroxidation/ferroptosis, with proven efficacy from past prospective clinical trials. As a biotechnology startup in the health care and pharmaceutical industries, FELIQS was founded in 2019. Currently, there is no publicly disclosed information regarding the last investment and investors in the startup.

Business keywords: Biotech, Ophthalmology, Preclinical-stage, Drug development, Retinopathy of prematurity, Age-related macular degeneration, Lipid peroxidation, Ferroptosis, Neonatology, Seed funding, Startup, Pharmaceutical science, Kyushu University, Drug discovery

No funding data available for FELIQS yet.

FELIQS Alternatives & Competitors

FELIQS vs
RevOpsis Therapeutics
RevOpsis Therapeutics

Harnessing a new era of multispecific biologics to discover ​ and develop breakthrough treatments

Seed
5 employees
Health Care, Life Sciences
FELIQS vs
RetroSense Therapeutics
RetroSense Therapeutics

Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel g...

Series B
1 employees
Biotechnology, Health and Wellness
FELIQS vs
Replenish, Inc.
Replenish, Inc. United States

Replenish, Inc. developed the world's smallest implantable, refillable drug pump for the $7 billion...

Venture round
10 employees
Biotechnology, Health Care

FAQ About FELIQS

An early clinical-stage biotech focusing on ophthalmology. Preparing to initiate phase 1b/2 study for ROP in 2025.
FELIQS was founded in 2019.
FELIQS is headquartered in Japan.
FELIQS operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on Biotech, Ophthalmology, Preclinical-stage and Drug development.
FELIQS has approximately 2 employees.
Top alternatives and competitors to FELIQS include RevOpsis Therapeutics, RetroSense Therapeutics, Replenish, Inc., OliX Pharmaceuticals, Inc., Inotek Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
FELIQS and RevOpsis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for FELIQS, https://bouncewatch.com/company/feliqs, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes